Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of threonyl-tRNA synthetases

Patent metadata

Field	Value
Publication number	US-9580706-B2
Application number	US-201514619722-A
Country	US
Kind code	B2
Filing date	Feb 11, 2015
Priority date	Apr 27, 2010
Publication date	Feb 28, 2017
Grant date	Feb 28, 2017

Abstract

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

First claim

We claim:

1. An isolated polynucleotide that encodes an aminoacyltRNA synthetase (AARS) polypeptide consisting of a sequence that is at least 95% identical to SEQ ID NO:12, 14, or 24, or a fragment thereof which is 140 or more contiguous amino acids of SEQ ID NO:12, 14, or 24, wherein the AARS polypeptide has an extracellular signaling activity, and wherein the polynucleotide is selected from (a) a cDNA polynucleotide and (b) a modified mRNA polynucleotide.

2. The isolated polynucleotide of claim 1 , wherein the AARS polypeptide is fused to a heterologous polypeptide.

3. The isolated polynucleotide of claim 2 , wherein the heterologous polypeptide is selected from the group consisting of purification tags, epitope tags, targeting sequences, signal peptides, membrane translocating sequences, and pharmacokinetic (PK) property modifiers.

4. The isolated polynucleotide of claim 1 , wherein the AARS polypeptide consists of SEQ ID NO:12, 14, or 24 or differs from SEQ ID NO:12, 14, or 24 by substitution, deletion, and/or addition of 1, 2, 3, 4, or 5 amino acids.

5. The isolated polynucleotide of claim 1 , which is at least 95% identical to SEQ ID NO:13, 15, or 25.

6. The isolated polynucleotide of claim 1 , comprising one or more transcriptional and/or translational control elements.

7. A pharmaceutical composition, comprising an isolated polynucleotide of claim 1 and a pharmaceutically-acceptable carrier, wherein the composition is substantially endotoxin-free.

8. The pharmaceutical composition of claim 7 , wherein the isolated polynucleotide is a modified mRNA polynucleotide that comprises at least one modified base.

9. The pharmaceutical composition of claim 7 , wherein the isolated polynucleotide is formulated for delivery encapsulated in a lipid particle, a liposome, a vesicle, a nanosphere, or a nanoparticle.

10. The pharmaceutical composition of claim 7 , which is suitable for intravenous administration.

11. A cellular composition or growth device, comprising
(i) an engineered population of cells in which at least one cell comprises a polynucleotide of claim 1 , wherein the cells are capable of growing in a serum-free medium, or
(ii) an engineered population of cells in which at least one cell comprises a polynucleotide of claim 1 , at least 10 liters of a serum-free growth medium, and a sterile container.

Assignees

• Atyr Pharma Inc
• Pangu Biopharma Ltd

Inventors

• Greene Leslie Ann
• Chiang Kyle P
• Hong Fei
• Vasserot Alain P
• Lo Wing-Sze
• Watkins Jeffry D
• Quinn Cheryl L
• Mendlein John D

Classifications

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• A61P3/08

  for glucose homeostasis (pancreatic hormones A61P5/48) · CPC title